These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2865112)

  • 41. Pharmacokinetics of biliary excretion of physostigmine in rat.
    Boyer AW; Somani SM
    Arch Int Pharmacodyn Ther; 1985 Dec; 278(2):180-92. PubMed ID: 4096611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individual variability in concentrations of urinary sulindac sulfide.
    Brandli DW; Sarkissian E; Ng SC; Paulus HE
    Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Probenecid-induced effects on bile flow and biliary excretion of 3H-ouabain.
    Erttmann RR; Damm KH
    Arch Int Pharmacodyn Ther; 1976 Sep; 223(1):96-106. PubMed ID: 999406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of methadone dose on the biliary excretion of methadone metabolites in the rat.
    Roerig DL; Hasegawa AT; Wang RI
    Drug Metab Dispos; 1976; 4(4):407-12. PubMed ID: 8297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats.
    Upton RA; Nguyen TL; Miller RD; Castagnoli N
    Anesth Analg; 1982 Apr; 61(4):313-6. PubMed ID: 6121522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats.
    Thijssen HH; Baars LG; Janssen GM
    Drug Metab Dispos; 1988; 16(5):744-8. PubMed ID: 2906600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide.
    Leite S; Martins NM; Dorta DJ; Curti C; Uyemura SA; dos Santos AC
    Basic Clin Pharmacol Toxicol; 2006 Oct; 99(4):294-9. PubMed ID: 17040214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alterations in biliary excretory function by streptozotocin-induced diabetes.
    Watkins JB; Dykstra TP
    Drug Metab Dispos; 1987; 15(2):177-83. PubMed ID: 2882974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sulindac sulfide inhibits Ras signaling.
    Herrmann C; Block C; Geisen C; Haas K; Weber C; Winde G; Möröy T; Müller O
    Oncogene; 1998 Oct; 17(14):1769-76. PubMed ID: 9778042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative pharmacokinetics of cefoperazone and cephradine in untreated streptozotocin diabetic rats.
    Nakashima E; Matsushita R; Takeda M; Nakanishi T; Ichimura F
    Drug Metab Dispos; 1992; 20(5):730-5. PubMed ID: 1358579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The disposition of sulindac.
    Duggan DE; Hare LE; Ditzler CA; Lei BW; Kwan KC
    Clin Pharmacol Ther; 1977 Mar; 21(3):326-35. PubMed ID: 300048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dimethyl sulfoxide inhibits metabolic activation of sulindac.
    Swanson BN; Mojaverian P; Boppana VK; Vlasses PH; Ferguson RK
    Ann N Y Acad Sci; 1983; 411():381-2. PubMed ID: 6576719
    [No Abstract]   [Full Text] [Related]  

  • 54. Altered hepatobiliary disposition of acetaminophen metabolites after phenobarbital pretreatment and renal ligation: evidence for impaired biliary excretion and a diffusional barrier.
    Brouwer KL; Jones JA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):657-64. PubMed ID: 2313593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of the biologically active form of sulindac.
    Duggan DE; Hooke KF; Risley EA; Shen TY; Arman CG
    J Pharmacol Exp Ther; 1977 Apr; 201(1):8-13. PubMed ID: 850147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversible acute decrease in renal function by NSAIDs in cirrhosis.
    Brater DC; Anderson SA; Brown-Cartwright D
    Am J Med Sci; 1987 Sep; 294(3):168-74. PubMed ID: 3661615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinetics of aluminum in rats. II: Dose-dependent urinary and biliary excretion.
    Xu ZX; Pai SM; Melethil S
    J Pharm Sci; 1991 Oct; 80(10):946-51. PubMed ID: 1784003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sulindac, reactive oxygen, and arthritis.
    Bodaness RS
    Med Hypotheses; 1979 Oct; 5(10):1129-30. PubMed ID: 522698
    [No Abstract]   [Full Text] [Related]  

  • 59. Age dependent differences in stimulation and compensation of renal and biliary transport processes. Correlation to the physicochemical properties of the exerted substances.
    Fleck C; Bräunlich H
    Arzneimittelforschung; 1990 Sep; 40(9):1047-53. PubMed ID: 2080942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-dose ceftriaxone kinetics in functionally anephric patients.
    Stoeckel K; McNamara PJ; Hoppe-Seyler G; Blumberg A; Keller E
    Clin Pharmacol Ther; 1983 May; 33(5):633-41. PubMed ID: 6301740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.